Literature DB >> 19740980

Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.

Anna Le Tortorec1, Stuart J D Neil.   

Abstract

Tetherin (CD317/BST-2), an interferon-induced membrane protein, restricts the release of nascent retroviral particles from infected cell surfaces. While human immunodeficiency virus type 1 (HIV-1) encodes the accessory gene vpu to overcome the action of tetherin, the lineage of primate lentiviruses that gave rise to HIV-2 does not. It has been previously reported that the HIV-2 envelope glycoprotein has a Vpu-like function in promoting virus release. Here we demonstrate that the HIV-2 Rod envelope glycoprotein (HIV-2 Rod Env) is a tetherin antagonist. Expression of HIV-2 Rod Env, but not that of HIV-1 or the closely related simian immunodeficiency virus (SIV) SIVmac1A11, counteracts tetherin-mediated restriction of Vpu-defective HIV-1 in a cell-type-specific manner. This correlates with the ability of the HIV-2 Rod Env to mediate cell surface downregulation of tetherin. Antagonism requires an endocytic motif conserved across HIV/SIV lineages in the gp41 cytoplasmic tail, but specificity for tetherin is governed by extracellular determinants in the mature Env protein. Coimmunoprecipitation studies suggest an interaction between HIV-2 Rod Env and tetherin, but unlike studies with Vpu, we found no evidence of tetherin degradation. In the presence of HIV-2 Rod Env, tetherin localization is restricted to the trans-Golgi network, suggesting Env-mediated effects on tetherin trafficking sequester it from virus assembly sites on the plasma membrane. Finally, we recapitulated these observations in HIV-2-infected CD4+ T-cell lines, demonstrating that tetherin antagonism and sequestration occur at physiological levels of Env expression during virus replication.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19740980      PMCID: PMC2772693          DOI: 10.1128/JVI.01515-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac).

Authors:  P A Luciw; K E Shaw; R E Unger; V Planelles; M W Stout; J E Lackner; E Pratt-Lowe; N J Leung; B Banapour; M L Marthas
Journal:  AIDS Res Hum Retroviruses       Date:  1992-03       Impact factor: 2.205

2.  The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses.

Authors:  S Bour; K Strebel
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

3.  Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.

Authors:  Janet L Douglas; Kasinath Viswanathan; Matthew N McCarroll; Jean K Gustin; Klaus Früh; Ashlee V Moses
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

4.  The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?

Authors:  S Bour; U Schubert; K Peden; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

5.  The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains.

Authors:  U Schubert; S Bour; A V Ferrer-Montiel; M Montal; F Maldarell; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

6.  Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC.

Authors:  J F Rowell; P E Stanhope; R F Siliciano
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

7.  A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells.

Authors:  C C LaBranche; M M Sauter; B S Haggarty; P J Vance; J Romano; T K Hart; P J Bugelski; M Marsh; J A Hoxie
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

8.  Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes.

Authors:  U Schubert; K A Clouse; K Strebel
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

9.  Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface.

Authors:  S S Molloy; L Thomas; J K VanSlyke; P E Stenberg; G Thomas
Journal:  EMBO J       Date:  1994-01-01       Impact factor: 11.598

10.  An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface.

Authors:  M M Sauter; A Pelchen-Matthews; R Bron; M Marsh; C C LaBranche; P J Vance; J Romano; B S Haggarty; T K Hart; W M Lee; J A Hoxie
Journal:  J Cell Biol       Date:  1996-03       Impact factor: 10.539

View more
  186 in total

1.  Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Authors:  Raphaël Vigan; Stuart J D Neil
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients.

Authors:  Helena Skar; Pedro Borrego; Timothy C Wallstrom; Mattias Mild; José Maria Marcelino; Helena Barroso; Nuno Taveira; Thomas Leitner; Jan Albert
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

3.  BST-2 diminishes HIV-1 infectivity.

Authors:  Jianyong Zhang; Chen Liang
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

Review 4.  Immune evasion by Kaposi's sarcoma-associated herpesvirus.

Authors:  Hye-Ra Lee; Stacy Lee; Preet M Chaudhary; Parkash Gill; Jae U Jung
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

5.  ATP1B3 Protein Modulates the Restriction of HIV-1 Production and Nuclear Factor κ Light Chain Enhancer of Activated B Cells (NF-κB) Activation by BST-2.

Authors:  Hironori Nishitsuji; Ryuichi Sugiyama; Makoto Abe; Hiroshi Takaku
Journal:  J Biol Chem       Date:  2015-12-22       Impact factor: 5.157

6.  The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.

Authors:  Abdul A Waheed; Maya Swiderski; Ali Khan; Ariana Gitzen; Ahlam Majadly; Eric O Freed
Journal:  J Biol Chem       Date:  2020-04-14       Impact factor: 5.157

7.  Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses.

Authors:  Julia Bitzegeio; Marissa Sampias; Paul D Bieniasz; Theodora Hatziioannou
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

Review 8.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

Review 9.  Interferon-stimulated genes: a complex web of host defenses.

Authors:  William M Schneider; Meike Dittmann Chevillotte; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2014-02-06       Impact factor: 28.527

10.  Regulation of porcine endogenous retrovirus release by porcine and human tetherins.

Authors:  Giada Mattiuzzo; Sabrina Ivol; Yasuhiro Takeuchi
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.